Piśmiennictwo:

 1. Zalecenia PTChP dotyczące rozpoznawania i leczenia POChP. Górecka D, Jassem E, Pierzchała W i wsp. Polskie Towarzystwo Chorób Płuc (PTChP). Pneumonol Alergol Pol. 2012; 80(3):220-54.
2. Kohansal R, Martinez-Camblor P, Agustí A i wsp. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med. 2009; 180(1):3-10.
3. Anthonisen NR, Skeans MA, Wise RA i wsp. Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005; 142(4): 233-9.
4. Wilson DH, Wakefield MA, Steven ID i wsp. "Sick of Smoking": evaluation of a targeted minimal smoking cessation intervention in general practice. Med J Aust. 1990; 152(10): 518-21.
5. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://www.goldcopd.org/
6. Górecka D, Bednarek M, Nowiński A i wsp. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest. 2003; 123(6):1916-23.
7. Bednarek M, Gorecka D, Wielgomas J i wsp. Smokers with airway obstruction are more likely to quit smoking. Thorax. 2006; 61(10):869-73.
8. Fagerstrom KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J Behav Med. 1989; 12(2):159-82.
9. 2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care. 2008; 53(9):1217-22.
10. Tashkin DP, Rennard S, Hays JT i wsp. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest. 2011; 139(3):591-9.
11. Silagy C, Lancaster T, Stead L i wsp. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146. Review. Update in: Cochrane Database Syst Rev. 2008;(1):CD000146.
12. Hurt RD, Sachs DP, Glover ED i wsp. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997; 337(17):1195-202.
13. Miller MR, Hankinson J, Brusasco V I wsp. Standardisation of spirometry. Eur Respir J. 2005; 26(2):319-38.
14. Bestall JC, Paul EA, Garrod R i wsp. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999; 54(7):581-6.
15. Jones PW, Harding G, Berry P i wsp. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009; 34(3):648-54.
16. Mackay AJ, Donaldson GC, Patel AR i wsp. Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med. 2012; 185(11):1218-24.
17. O'Donnell DE, McGuire M, Samis L i wsp. The impact of exercise reconditioning on breathlessness in severe chronic airflow limitation. Am J Respir Crit Care Med. 1995; 152:2005-13.
18. Goldstein RS, Gort EH, Stubbing D i wsp. Randomised controlled trial of respiratory rehabilitation. Lancet. 1994; 344(8934):1394-7.
19. Puhan MA, Gimeno-Santos E, Scharplatz M i wsp. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011; (10):CD005305.
20. Caramori G, Adcock IM, Papi A. Clinical definition of COPD exacerbations and classification of their severity. South Med J. 2009; 102(3):277-82.
21. Anthonisen NR, Manfreda J, Warren CP i wsp. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106(2):196-204.
22. Niewoehner DE, Erbland ML, Deupree RH i wsp. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999; 340(25):1941-7.
23. Bertoletti L, Quenet S, Mismetti P i wsp. Clinical presentation and outcome of venous thromboembolism in COPD. Eur Respir J. 2012; 39(4):862-8.
24. Zawilska K, Jaeschke R, Tomkowski W i wsp. Polish guidelines for the prevention and treatment of venous thromboembolism: 2009 update. Pol Arch Med Wewn. 2009;119 Suppl 1:1-69.
25. Burge PS, Calverley PM, Jones PW i wsp. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000; 320(7245):1297-303.
26. Szafranski W, Cukier A, Ramirez A, i wsp. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003; 21(1):74-81.
27. Tashkin DP. Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial. Expert Rev Respir Med. 2010; 4(3):279-89.
28. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Sep 12;9:CD009157.
29. Rennard SI, Anderson W, ZuWallack R i wsp. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 163(5):1087-92.
30. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010; 11:149.
31. Wedzicha JA, Rabe KF, Martinez FJ i wsp. Efficacy of roflumilast in the chronic obstructive pulmonary disease frequent exacerbator phenotype. Chest. 2012 Nov 1. doi: 10.1378/chest.12-1489. [Epub ahead of print]
32. Schembri S, Morant S, Winter JH i wsp. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD.Thorax. 2009; 64(7):567-72.
33. Walters JA, Smith S, Poole P i wsp. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2010; (11):CD001390.
34. Yorgancioglu A. Indacaterol in chronic obstructive pulmonary disease: an update for clinicians.Ther Adv Chronic Dis. 2012; 3(1): 25-36.
35. Baye J. Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. P T. 2012; 37(3):149-61.
36. Barnes PJ. Development of New Drugs for COPD. Curr Med Chem. 2012 Sep 3. [Epub ahead of print].